Aktienanalyse zu NuCana PLC (NCNA)NCNANuCana PLC

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

NuCana PLC (NCNA) is not a good buy right now due to its significant financial losses and poor technical indicators. The stock has a current price of $0.94, which is close to its 52-week low of $0.90, indicating a lack of upward momentum. Additionally, the RSI is at 32.144, suggesting that the stock is oversold, but this could also indicate ongoing weakness rather than an imminent recovery. The company has reported a staggering year-to-date change of -74.24%, reflecting severe challenges in its financial performance, including a gross profit of £0.00 in recent quarters and a forward P/E ratio of 0, which indicates no expected earnings growth. The main risk is the continued negative net income, with the latest reported loss of £3.08 million in Q2 2026, which raises concerns about the company's viability moving forward.

4 analysts cover NCNA: 4 rate it Buy, 0 Hold and 0 Sell.